BridgeMD
Tests treatment safety and results for Herpes Zoster
Official title Efficacy and Safety of Brivudine in the Treatment of Herpes Zoster
ClinicalTrials.gov ID: NCT07099157
What this study is testing
What is Brivudine?
Brivudine is an investigational medicine, given as an once-daily, being studied as a potential treatment for herpes zoster.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- This multicenter RCT aims to compare the efficacy and safety of Brivudine versus Famciclovir in treating acute herpes zoster. Primary objective: Evaluate pain reduction via Numeric Pain Rating Scale (NPRS) at Day 30.
- Phase 4: studies an already-approved treatment
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Age ≥18 years, regardless of gender;
- Signed Informed Consent Form;
- Female people must not plan for pregnancy or oocyte donation from screening until 1 week after the last dose and must voluntarily adopt highly...
- Barrier methods: Condom or barrier cap (diaphragm or cervical cap);
- Intrauterine device (IUD) or intrauterine system (IUS);
You likely can't join if
- Allergy to brivudine, famciclovir, or penciclovir;
- Current use of fluorouracil agents (e.g., 5-fluorouracil, capecitabine, tegafur, flucytosine);
- Cancer patients currently undergoing chemotherapy;
- Pregnant or lactating women;
- Parkinson's disease;
- Any condition deemed inappropriate for study participation by the investigator.
See the full eligibility criteria
- Age ≥18 years, regardless of gender;
- Signed Informed Consent Form;
- Female people must not plan for pregnancy or oocyte donation from screening until 1 week after the last dose and must voluntarily adopt highly effective physical contraception; male people must not plan for fertility or...
- Barrier methods: Condom or barrier cap (diaphragm or cervical cap);
- Intrauterine device (IUD) or intrauterine system (IUS);
- Surgical sterilization (bilateral oophorectomy with/without hysterectomy, total hysterectomy, bilateral tubal ligation, or vasectomy) performed ≥6 months prior to the first dose in the subject or their partner;
- Other investigator-confirmed highly effective physical contraception.
- Allergy to brivudine, famciclovir, or penciclovir;
- Current use of fluorouracil agents (e.g., 5-fluorouracil, capecitabine, tegafur, flucytosine);
- Cancer patients currently undergoing chemotherapy;
- Pregnant or lactating women;
- Parkinson's disease;
- Any condition deemed inappropriate for study participation by the investigator.
The study team makes the final eligibility decision.
Where it's taking place
- Beijing, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Beijing, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.